Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Intraocular Melanoma: early-phase trial registry

A small indexed set (6 trials) with no open enrollment listed right now.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count

Intraocular Melanoma: 6 US clinical trials tracked, none currently recruiting.

Intraocular Melanoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition intraocular-melanoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #2866 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Intraocular Melanoma (this)0%
Open-enrollment share among volume-matched conditions near Intraocular Melanoma

Intraocular Melanoma has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Intraocular Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Intraocular Melanoma is recruiting below its size-band peers.

    0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Intraocular Melanoma research.

    Memorial Sloan Kettering Cancer Center accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Intraocular Melanoma research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Intraocular Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

fine-needle aspiration Procedure
1 trials
MART-1 antigen Biological
1 trials
gp100 antigen Biological
1 trials
recombinant interleukin-12 Biological
1 trials
intramuscularly (IM injection) Other
1 trials
The Dermal PowderMed® devices Device
1 trials
mouse gp100 plasmid DNA vaccine Biological
1 trials
incomplete Freund's adjuvant Biological
1 trials

US sites by state

Facility locations filed on Intraocular Melanoma trials. A trial with sites in several states counts in each.

Ohio 2 trials
New York 2 trials
Maryland 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Intraocular Melanoma page

6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Intraocular Melanoma condition card totals 6 registered trials; most-linked intervention fine-needle aspiration; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.